Latest & greatest articles for testosterone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on testosterone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on testosterone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for testosterone

61. Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment. Full Text available with Trip Pro

Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment. Most cognitive functions decline with age. Prior studies suggest that testosterone treatment may improve these functions.To determine if testosterone treatment compared with placebo is associated with improved verbal memory and other cognitive functions in older men with low testosterone and age-associated memory impairment (AAMI).The Testosterone Trials (TTrials) were 7 trials (...) to assess the efficacy of testosterone treatment in older men with low testosterone levels. The Cognitive Function Trial evaluated cognitive function in all TTrials participants. In 12 US academic medical centers, 788 men who were 65 years or older with a serum testosterone level less than 275 ng/mL and impaired sexual function, physical function, or vitality were allocated to testosterone treatment (n = 394) or placebo (n = 394). A subgroup of 493 men met criteria for AAMI based on baseline subjective

2017 JAMA Controlled trial quality: predicted high

62. Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines

Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines Published on: February 9, 2017 Project Number: RA0892-000 Product Line: Research Type: Drug Report (...) Type: Reference List Result type: Report Question What is the clinical effectiveness of testosterone for patients with depression? What is the clinical effectiveness of testosterone for patients with post-traumatic stress disorder? What is the clinical effectiveness of testosterone for patients with fibromyalgia? What are the evidence-based guidelines for the use of testosterone for patients with depression, PTSD, or fibromyalgia? Key Message Two systematic reviews, two randomized controlled trials

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

63. Distribution of Salivary Testosterone in Men and Women in a British General Population-Based Sample: The Third National Survey of Sexual Attitudes and Lifestyles (Natsal-3) Full Text available with Trip Pro

Distribution of Salivary Testosterone in Men and Women in a British General Population-Based Sample: The Third National Survey of Sexual Attitudes and Lifestyles (Natsal-3) Measurement of salivary testosterone (Sal-T) to assess androgen status offers important potential advantages in epidemiological research. The utility of the method depends on the interpretation of the results against robustly determined population distributions, which are currently lacking.To determine age-specific Sal-T

2017 Journal of the Endocrine Society

64. The effect of testosterone replacement therapy on endothelial health-related parameters in men with late onset hypogonadism

The effect of testosterone replacement therapy on endothelial health-related parameters in men with late onset hypogonadism Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2017 PROSPERO

65. What is the effect of testosterone replacement on sexual dysfunction and quality of life in adult men with opioid induced androgen deficiency? A systematic review

What is the effect of testosterone replacement on sexual dysfunction and quality of life in adult men with opioid induced androgen deficiency? A systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2017 PROSPERO

66. Testosterone therapy for high risk prostate cancer survivors: a systematic review

Testosterone therapy for high risk prostate cancer survivors: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2017 PROSPERO

69. Transdermal testosterone supplementation and poor ovarian responders: a real and promising approach for improving IVF outcome, or just a clinical mirage? A meta-analysis of randomized trials

Transdermal testosterone supplementation and poor ovarian responders: a real and promising approach for improving IVF outcome, or just a clinical mirage? A meta-analysis of randomized trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2017 PROSPERO

70. Systematic review of testosterone replacement in obese men with low testosterone levels

Systematic review of testosterone replacement in obese men with low testosterone levels Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2017 PROSPERO

71. Testosterone therapy and cardiovascular risk

Testosterone therapy and cardiovascular risk Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing and effect

2017 PROSPERO

72. Testosterone replacement therapy for sexual dysfunction in men with type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials

Testosterone replacement therapy for sexual dysfunction in men with type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2017 PROSPERO

73. Testosterone level and cognitive functioning in adult men: a systematic review and meta-analysis

Testosterone level and cognitive functioning in adult men: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2017 PROSPERO

74. Testosterone treatment and risk of venous thromboembolism: population based case-control study. Full Text available with Trip Pro

Testosterone treatment and risk of venous thromboembolism: population based case-control study.  To determine the risk of venous thromboembolism associated with use of testosterone treatment in men, focusing particularly on the timing of the risk. Population based case-control study SETTING:  370 general practices in UK primary care with linked hospital discharge diagnoses and in-hospital procedures and information on all cause mortality. 19 215 patients with confirmed venous thromboembolism (...) (comprising deep venous thrombosis and pulmonary embolism) and 909 530 age matched controls from source population including more than 2.22 million men between January 2001 and May 2013. Three mutually exclusive testosterone exposure groups were identified: current treatment, recent (but not current) treatment, and no treatment in the previous two years. Current treatment was subdivided into duration of more or less than six months. Rate ratios of venous thromboembolism in association with current

2016 BMJ

75. Testosterone Therapy Among Prostate Cancer Survivors Full Text available with Trip Pro

Testosterone Therapy Among Prostate Cancer Survivors The use of testosterone in men with a history of prostate cancer remains controversial in light of established findings linking androgens to prostate cancer growth. However, hypogonadism significantly affects quality of life and has negative sequelae, and the risks and benefits of testosterone therapy might be worthwhile to consider in all men, even those with a history of high-risk prostate cancer.To discuss the effects of testosterone (...) on the prostate and the use of testosterone therapy in hypogonadal men with a history of prostate cancer.Review of the literature examining the effects of testosterone on the prostate and the efficacy and safety of exogenous testosterone in men with a history of prostate cancer.Summary of effects of exogenous and endogenous testosterone on prostate tissue in vitro and in vivo, with a focus on effects in men with a history of prostate cancer.Testosterone therapy ameliorates the symptoms of hypogonadism

2016 Sexual medicine reviews

76. Is Testosterone Detrimental to Renal Function? Full Text available with Trip Pro

Is Testosterone Detrimental to Renal Function? 29318206 2019 02 26 2468-0249 1 4 2016 Nov Kidney international reports Kidney Int Rep Is Testosterone Detrimental to Renal Function? 306-310 10.1016/j.ekir.2016.07.004 Filler Guido G Department of Paediatrics, Children's Hospital at London Health Science Centre, London, Ontario, Canada. Department of Pathology and Laboratory Medicine, University of Western Ontario, London, Ontario, Canada. Department of Medicine, University of Western Ontario

2016 Kidney international reports

77. Testosterone Treatment in Older Men. (Abstract)

Testosterone Treatment in Older Men. 27406354 2016 07 14 2018 12 02 1533-4406 375 1 2016 07 07 The New England journal of medicine N. Engl. J. Med. Testosterone Treatment in Older Men. 90 10.1056/NEJMc1603665 Snyder Peter J PJ Ellenberg Susan S SS Farrar John T JT eng Letter Comment United States N Engl J Med 0255562 0028-4793 3XMK78S47O Testosterone AIM IM N Engl J Med. 2016 Feb 18;374(7):611-24 26886521 N Engl J Med. 2016 Jul 7;375(1):88 27406355 N Engl J Med. 2016 Jul 7;375(1):89-90 27406358 (...) N Engl J Med. 2016 Jul 7;375(1):88-9 27406356 N Engl J Med. 2016 Jul 7;375(1):89 27406357 Fatigue drug therapy Hormone Replacement Therapy Humans Male Sexual Behavior drug effects Testosterone therapeutic use Walking physiology 2016 7 14 6 0 2016 7 15 6 0 2016 7 15 6 1 ppublish 27406354 10.1056/NEJMc1603665 10.1056/NEJMc1603665#SA5

2016 NEJM

78. Testosterone Treatment in Older Men. Full Text available with Trip Pro

Testosterone Treatment in Older Men. 27406355 2016 07 14 2018 12 02 1533-4406 375 1 2016 07 07 The New England journal of medicine N. Engl. J. Med. Testosterone Treatment in Older Men. 88 10.1056/NEJMc1603665 Perls Thomas T TT Boston University School of Medicine, Boston, MA thperls@bu.edu. eng Letter Comment United States N Engl J Med 0255562 0028-4793 3XMK78S47O Testosterone AIM IM N Engl J Med. 2016 Feb 18;374(7):611-24 26886521 N Engl J Med. 2016 Jul 7;375(1):90 27406354 Fatigue drug (...) therapy Hormone Replacement Therapy Humans Male Sexual Behavior drug effects Testosterone therapeutic use Walking physiology 2016 7 14 6 0 2016 7 15 6 0 2016 7 15 6 1 ppublish 27406355 10.1056/NEJMc1603665 10.1056/NEJMc1603665#SA1

2016 NEJM

79. Testosterone Treatment in Older Men. Full Text available with Trip Pro

Testosterone Treatment in Older Men. 27406356 2016 07 14 2018 12 02 1533-4406 375 1 2016 07 07 The New England journal of medicine N. Engl. J. Med. Testosterone Treatment in Older Men. 88-9 10.1056/NEJMc1603665 Stavropoulos Konstantinos K Aristotle University of Thessaloniki, Thessaloniki, Greece kostasimprialos@hotmail.com. Boutari Chrysoula C Aristotle University of Thessaloniki, Thessaloniki, Greece kostasimprialos@hotmail.com. Imprialos Konstantinos K Aristotle University of Thessaloniki (...) , Thessaloniki, Greece kostasimprialos@hotmail.com. eng Letter Comment United States N Engl J Med 0255562 0028-4793 3XMK78S47O Testosterone AIM IM N Engl J Med. 2016 Feb 18;374(7):611-24 26886521 N Engl J Med. 2016 Jul 7;375(1):90 27406354 Fatigue drug therapy Hormone Replacement Therapy Humans Male Sexual Behavior drug effects Testosterone therapeutic use Walking physiology 2016 7 14 6 0 2016 7 15 6 0 2016 7 15 6 1 ppublish 27406356 10.1056/NEJMc1603665 10.1056/NEJMc1603665#SA2

2016 NEJM

80. Testosterone Treatment in Older Men. Full Text available with Trip Pro

Testosterone Treatment in Older Men. 27406357 2016 07 14 2018 12 02 1533-4406 375 1 2016 07 07 The New England journal of medicine N. Engl. J. Med. Testosterone Treatment in Older Men. 89 10.1056/NEJMc1603665 Mata Douglas A DA Brigham and Women's Hospital, Boston, MA dmata@bwh.harvard.edu. Ramasamy Ranjith R University of Miami Miller School of Medicine, Miami, FL. Lipshultz Larry I LI Baylor College of Medicine, Houston, TX. eng Letter Comment United States N Engl J Med 0255562 0028-4793 (...) 3XMK78S47O Testosterone AIM IM N Engl J Med. 2016 Feb 18;374(7):611-24 26886521 N Engl J Med. 2016 Jul 7;375(1):90 27406354 Fatigue drug therapy Hormone Replacement Therapy Humans Male Sexual Behavior drug effects Testosterone therapeutic use Walking physiology 2016 7 14 6 0 2016 7 15 6 0 2016 7 15 6 1 ppublish 27406357 10.1056/NEJMc1603665 10.1056/NEJMc1603665#SA3

2016 NEJM